STOCK TITAN

Humacyte Inc - HUMA STOCK NEWS

Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.

About Humacyte Inc

Humacyte Inc (NASDAQ: HUMA) is a clinical-stage biotechnology company focused on developing a disruptive platform to create universally implantable, bioengineered human tissues and organ systems. The company is dedicated to transforming vascular surgery and regenerative medicine by engineering acellular tissues that can be used in a wide array of medical applications.

Core Business and Technology Platform

At its core, Humacyte leverages advanced tissue engineering techniques to develop acellular tissues that are designed to replace or repair damaged vascular conduits. Its flagship product candidates, which include acellular tissue engineered vessels (ATEVs), are developed for various clinical applications such as vascular trauma repair, arteriovenous access for hemodialysis, and treatments for peripheral artery disease. By removing cellular elements from its tissues, Humacyte minimizes immunogenicity while simultaneously enabling host cell repopulation and remodeling, which are critical for long-term functionality.

Innovative Approach to Vascular Repair

Humacyte has engineered its products to be off-the-shelf solutions, addressing critical needs in emergency vascular repair. This innovative approach contrasts with conventional methods that involve autologous tissue harvesting, which can lead to additional complications in time-sensitive situations. The company’s bioengineered tissues provide a consistent and readily available alternative, reducing the operative time and potential risks associated with traditional procedures.

Clinical Development and Regulatory Engagement

The company is in advanced stages of clinical research, with multiple product candidates undergoing late-stage clinical trials across several vascular applications. Humacyte has actively engaged with regulatory agencies and obtained key designations that underscore the potential of its products in addressing significant unmet medical needs. These include priority reviews and special designations from regulatory authorities, which highlight the innovation and safety profile of its engineered tissues.

Pipeline Diversification and Strategic Partnerships

Beyond its initial portfolio focused on vascular applications, Humacyte is expanding its pipeline to include other therapeutic areas such as coronary artery bypass grafting and pediatric heart surgery. Its ongoing collaborations with leading biotechnology partners further enhance its research and development capabilities, particularly in combining gene editing technologies with tissue engineering for novel solutions in regenerative medicine.

Competitive Position and Market Significance

Humacyte occupies a unique position in the biotechnology and regenerative medicine landscape. Its emphasis on universally implantable, acellular tissue constructs differentiates it from traditional biologics and synthetic graft options. The combination of advanced tissue engineering, robust clinical validation, and strategic regulatory engagement makes Humacyte a significant player in pioneering next-generation treatments for critical vascular conditions.

Business Model and Revenue Generation

The company’s business model centers around the development and eventual commercialization of its bioengineered tissue products. With a focus on quality manufacturing and leveraging strategic partnerships, Humacyte aims to bring its shelf-ready product candidates to market, providing essential clinical solutions while setting new standards in patient care and surgical outcomes.

Research and Development Focus

  • Acellular Tissue Engineering: Utilizing a method that removes immunogenic cellular components while promoting host cell adaptation.
  • Vascular Conduits: Designing engineered vessels for diverse vascular applications including trauma and hemodialysis access.
  • Clinical Innovation: Advancing products through rigorous clinical trials that validate safety, efficacy, and mechanical durability.
  • Regenerative Medicine: Pioneering advancements that integrate tissue engineering with innovative approaches to address chronic conditions.

Commitment to Advancing Patient Care

Humacyte is committed to improving patient outcomes by offering revolutionary alternatives to conventional surgical procedures. Its research-driven approach and focus on transforming the practice of medicine underscore the company’s dedication to both scientific excellence and the betterment of patient care.

Conclusion

With a strong foundation in biotechnology innovation and a pipeline that addresses a wide range of vascular challenges, Humacyte Inc represents a forward-thinking company in regenerative medicine. Its comprehensive approach to developing universally implantable bioengineered tissues not only meets critical unmet clinical needs but also sets new paradigms in the future of vascular repair and patient safety.

Rhea-AI Summary

Humacyte (NASDAQ: HUMA) announced its Q4 and full-year 2024 financial results, highlighting the FDA approval of Symvess™ for extremity vascular trauma treatment in December 2024. The company has initiated commercial launch with first sales in February 2025, with 34 hospitals starting the Value Analysis Committee approval process and three hospitals already approving purchases.

Financial highlights show no revenue for Q4 and full-year 2024. R&D expenses were $20.7M in Q4 2024 and $88.6M for the full year. Net loss increased to $148.7M for 2024, compared to $110.8M in 2023. The company reported $95.3M in cash and equivalents as of December 31, 2024, with an additional $46.6M raised through a public offering in March 2025.

Key developments include positive Phase 3 trial results for arteriovenous access in dialysis patients, plans for a supplemental BLA submission in H2 2026, and an upcoming IND filing in 2025 for coronary artery bypass grafting studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
-
Rhea-AI Summary

Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissue at commercial scale, has scheduled its Q4 and full-year 2024 financial results release for March 28, 2025.

The company will host a webcast and conference call at 8:30 a.m. ET on the same day. The webcast will be available 15 minutes before the call begins, and a replay will be accessible on the company's investor relations website for at least 30 days following the broadcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.43%
Tags
conferences earnings
-
Rhea-AI Summary

Humacyte (Nasdaq: HUMA) has announced the pricing of a public offering of 25,000,000 shares of common stock at $2.00 per share, expecting to raise gross proceeds of $50 million. The offering is set to close around March 27, 2025.

The company has granted underwriters a 30-day option to purchase up to an additional 3,750,000 shares. TD Cowen, Barclays, and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company are acting as lead managers.

The net proceeds will be used to fund the commercialization of SYMVESS™ in vascular trauma indication, development of product candidates in Humacyte's pipeline, and for working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.43%
Tags
Rhea-AI Summary

Humacyte (Nasdaq: HUMA) has announced an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase up to an additional 15% of offered shares. TD Cowen, Barclays, and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company act as lead managers.

The commercial-stage biotechnology platform company, focused on developing universally implantable bioengineered human tissues, intends to use the proceeds to fund:

  • Commercialization of SYMVESS™ in vascular trauma indication
  • Development of product candidates in pipeline
  • Working capital and general corporate purposes

The offering will be made through a shelf registration statement previously filed and declared effective by the SEC. The final size, terms, and completion of the offering remain subject to market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.43%
Tags
-
Rhea-AI Summary

Humacyte (Nasdaq: HUMA) announced the publication of a Budget Impact Model (BIM) for Symvess in the Journal of Medical Economics. Symvess, a bioengineered human tissue for vascular repair, received FDA approval on December 19, 2024.

The economic analysis reveals significant cost savings for both trauma centers and payers. For trauma centers, the average per-patient cost with Symvess is $121,615 (including $29,500 purchase price), compared to $154,722 for cryopreserved allograft, $140,428 for bovine xenograft, and $137,213 for prosthetic grafts. For commercial payers, Symvess costs $94,165 per patient versus $181,127 for prosthetic grafts.

Cost savings are primarily attributed to reduced rates of vascular conduit infection and amputation. The model incorporated data from the PROOVIT registry, hospital charges, insurance claims, and expert opinion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.15%
Tags
none
-
Rhea-AI Summary

Trestle Biotherapeutics and Humacyte (Nasdaq: HUMA) have announced a research collaboration to explore technology synergies for bioengineering vascularized organs for transplantation. The partnership will investigate the integration of Trestle Bio's biofabricated human kidney tissues with Humacyte's FDA-approved ATEV™ technology.

The collaboration aims to develop a human bioengineered kidney with vascular perfusion, targeting the significant global need in kidney disease treatment. Currently, over 800 million patients worldwide suffer from chronic kidney disease, with 600,000 US patients dependent on dialysis. While approximately 100,000 patients are on the transplant waiting list, only 25,000 successful transplants occur annually.

Trestle Bio's technology focuses on developing implantable bioengineered kidney tissue designed to reduce ESRD patients' dialysis dependency. This collaboration follows Humacyte's recent FDA approval for ATEV™ as a vascular conduit for extremity arterial injury treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
none
Rhea-AI Summary

Humacyte (Nasdaq: HUMA) has announced an upcoming investor event, scheduled for March 6, 2025, at 12:00 PM ET in New York, available both in-person and virtually. The event will spotlight Symvess, their groundbreaking bioengineered human tissue product that received FDA approval in December 2024.

The presentation will feature vascular surgery experts Dr. Michael Curi from Rutgers New Jersey Medical School and Dr. Sammy Siada from UCSF Fresno, alongside company management. They will discuss commercial strategies and initial market performance of Symvess, a first-in-class universally implantable vascular conduit.

The FDA approved Symvess for adult use in extremity arterial injury cases requiring urgent revascularization to prevent limb loss, specifically when autologous vein grafts aren't viable. The event will conclude with a Q&A session, and a webcast replay will be available on Humacyte's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.15%
Tags
conferences
-
Rhea-AI Summary

Humacyte (Nasdaq: HUMA), a commercial-stage biotechnology platform company focused on bioengineered human tissues, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation will take place on March 4, 2025 at 3:10 p.m. EST at the Marriott Copley Place in Boston, MA.

Dr. Laura Niklason, the company's Founder, President, and CEO, will lead the presentation. The management team will also be available for one-on-one meetings during the conference. Investors and interested parties can access the presentation via webcast, with a replay available for a time on Humacyte's website under the Events & Presentations section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
-
Rhea-AI Summary

Humacyte (Nasdaq: HUMA) has been granted U.S. Patent No. 12,195,711 for its 'Drawer System for Cultivating Tissue,' covering key aspects of their bioreactor manufacturing system until 2040. The patent specifically relates to the production of Symvess, their first-in-class bioengineered human tissue designed as a universally implantable vascular conduit.

The company operates an 83,000 square foot bioprocessing facility capable of manufacturing human tissue at commercial scale. Notably, the FDA granted full approval for Symvess on December 19, 2024, for use in adults requiring urgent revascularization due to extremity arterial injury when autologous vein grafts aren't feasible.

Symvess offers an off-the-shelf solution that eliminates the need for harvesting veins from patients during acute trauma. The product is currently undergoing clinical trials for arteriovenous access in hemodialysis and peripheral artery disease, with preclinical development for coronary artery bypass grafts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
Rhea-AI Summary

Humacyte (HUMA) has launched Symvess, its FDA-approved bioengineered human tissue vascular conduit, for treating extremity arterial injuries. The product received full FDA approval on December 19, 2024, and is now authorized for commercial shipments.

Twenty-one hospitals have initiated the Value Analysis Committee (VAC) approval process, with two already completing their review and approving Symvess purchases. Some hospitals plan to purchase while VAC review is ongoing. The product has shown positive results in clinical studies, including high patency rates and low amputation and infection rates.

According to Humacyte's Budget Impact Model (BIM), Symvess treatment is estimated to be more cost-effective than synthetic grafts, cryopreserved allografts, or xenografts, primarily due to reduced amputation and infection rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.83%
Tags
none

FAQ

What is the current stock price of Humacyte (HUMA)?

The current stock price of Humacyte (HUMA) is $1.35 as of April 4, 2025.

What is the market cap of Humacyte (HUMA)?

The market cap of Humacyte (HUMA) is approximately 213.3M.

What is Humacyte Inc's core business?

Humacyte Inc is a clinical-stage biotechnology company focused on developing universally implantable bioengineered human tissues for a range of vascular applications.

What products is Humacyte known for?

The company is known for its acellular tissue engineered vessels (ATEVs), which are designed for applications such as vascular trauma repair, hemodialysis access, and peripheral artery disease.

How does Humacyte's technology differ from traditional methods?

Unlike conventional treatments that rely on harvesting autologous tissue, Humacyte's acellular tissues are off-the-shelf solutions that minimize patient risk and reduce surgical time by eliminating the need for additional tissue harvesting.

What clinical areas does Humacyte target?

Humacyte focuses on vascular applications including trauma repair, arteriovenous fistula for hemodialysis, peripheral artery disease, and is expanding into areas such as coronary bypass grafting and pediatric heart surgery.

How is Humacyte advancing its research and development?

The company invests in robust clinical trials and collaborates with strategic partners to enhance its platform technologies, integrating advanced tissue engineering and cell technologies to support its pipeline.

Has Humacyte received any regulatory designations?

Yes, Humacyte has secured key regulatory designations and priority reviews for its products, which underscore the potential and safety profile of its engineered vascular tissues.

What is the significance of acellular tissue engineering?

Acellular tissue engineering allows for the creation of implantable vascular conduits that minimize immunogenic reactions while promoting natural host cell repopulation and remodeling, leading to improved long-term outcomes.

How does Humacyte position itself in the competitive biotechnological landscape?

Humacyte differentiates itself by offering off-the-shelf, bioengineered tissue solutions that address critical unmet medical needs, supported by extensive clinical data and a strong commitment to research and development.
Humacyte Inc

Nasdaq:HUMA

HUMA Rankings

HUMA Stock Data

213.29M
95.67M
26.87%
35.02%
19.8%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
DURHAM